• Mineralys Therapeutics recently presented post hoc proteomic data from its Phase 3 Launch-HTN and Phase 2b Advance-HTN trials at ENDO 2026, showing lorundrostat’s impact on renin-angiotensin-aldosterone system biomarkers and several heart failure risk markers after 12 weeks of treatment.
• The finding that lorundrostat reduced multiple candidate causal heart failure biomarkers, including NT-proBNP, adds mechanistic support for exploring heart failure and other cardiorenal indications beyond hypertension.
• We’ll now examine how lorundrostat’s biomarker effects supporting potential heart failure benefits may influence Mineralys Therapeutics’ broader investment narrative.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Mineralys Therapeutics Investment Narrative Recap

To own Mineralys Therapeutics, you need to believe lorundrostat can secure an approval and meaningful use in uncontrolled and resistant hypertension, then gradually extend into other aldosterone driven conditions. The new ENDO 2026 biomarker data strengthens the mechanistic story around potential heart failure benefits, but the main near term catalyst remains the FDA review ahead of the 22 December 2026 PDUFA date, while regulatory risk and single drug dependence still dominate the downside.

The recent US$500 million term loan facility announced on 3 June 2026 looks especially relevant here, as it is structured around key FDA approval milestones and secured against core assets. Combined with the follow on equity raise of about US$150.0 million, this financing gives Mineralys more room to fund lorundrostat’s launch and cardiorenal development work, but it also increases the stakes if approval is delayed or uptake is slower than expected...

Mineralys Therapeutics' narrative projects $215.7 million revenue and $23.5 million earnings by 2029. This requires an earnings increase of about $195 million from -$171.4 million today.

Uncover how Mineralys Therapeutics' forecasts yield a $50.88 fair value, a 99% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming only about US$146.6 million of revenue by 2029 and a very high implied PE multiple, so if payer controls, a stronger early competitor or mixed real world data constrain lorundrostat more than its current clinical and biomarker package suggests, your view on risk could look quite different from consensus.

Explore 4 other fair value estimates on Mineralys Therapeutics - why the stock might be worth just $49.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Mineralys Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.

No Opportunity In Mineralys Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.